DUBLIN – Immatics Biotechnologies GmbH is pocketing $54 million up front and could earn up to $1.65 billion more in development, regulatory and commercial milestones from a three-product immuno-oncology research collaboration and license agreement with Genmab A/S. The two companies will pool their respective capabilities in cancer target discovery, T-cell receptor (TCR) engineering and antibody engineering to develop bispecific protein-based therapeutics that will target both intracellular tumor-associated peptides (Tumaps) and T cells.